| Symbol | TVRD |
|---|---|
| Name | TVARDI THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3 SUGAR CREEK CTR. BLVD.,SUITE 525, SUGAR LAND, Texas, 77478, United States |
| Telephone | +1 713 - 489-8654 |
| Fax | — |
| — | |
| Website | https://www.caratherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001346830 |
| Description | Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Caras most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Caras objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. Additional info from NASDAQ: |
(10% Negative) TVARDI THERAPEUTICS, INC. (TVRD) Reports Q3 2026 Financial Results
Read moreTvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Read more(10% Negative) TVARDI THERAPEUTICS, INC. (TVRD) Announces Delay in indication Trials for ulcerative colitis (UC) Due to Regulatory Process, Safety Review
Read moreTvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
Read moreNew Form 424B5 - Tvardi Therapeutics, Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001104659-26-084619 <b>Size:</b> 742 KB
Read moreShiff Susan Ph.D. 🟢 acquired 6.0K shares (1 derivative) of Tvardi Therapeutics, Inc. (TVRD) at $2.78 Transaction Date: Jun 09, 2026 | Filing ID: 000002
Read moreSmith Cynthia 🟢 acquired 6.0K shares (1 derivative) of Tvardi Therapeutics, Inc. (TVRD) at $2.78 Transaction Date: Jun 09, 2026 | Filing ID: 000002
Read moreShah Sujal 🟢 acquired 6.0K shares (1 derivative) of Tvardi Therapeutics, Inc. (TVRD) at $2.78 Transaction Date: Jun 09, 2026 | Filing ID: 000002
Read moreWYZGA MICHAEL S 🟢 acquired 6.0K shares (1 derivative) of Tvardi Therapeutics, Inc. (TVRD) at $2.78 Transaction Date: Jun 09, 2026 | Filing ID: 000003
Read more(99% Neutral) TVARDI THERAPEUTICS, INC. (TVRD) Announces Regulatory Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STA… | Phase1 | Head and Neck Squamous Cell Carcinoma | Withdrawn | 2025-09-23 | 2025-09-23 | ClinicalTrials.gov |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With… | Early_Phase1 | Squamous Cell Carcinoma of Head and Neck | Withdrawn | 2025-06-20 | 2025-11-13 | ClinicalTrials.gov |
| NCT06141031 | Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally A… | Phase1 | Pancreatic Cancer | Recruiting | 2024-01-16 | 2029-06-30 | ClinicalTrials.gov |
| NCT05671835 | Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis | Phase2 | Idiopathic Pulmonary Fibrosis | Completed | 2023-05-15 | 2025-08-14 | ClinicalTrials.gov |
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Local… | Phase1 | Hepatocellular Carcinoma | Recruiting | 2023-03-23 | 2027-03-10 | ClinicalTrials.gov |
| NCT05384119 | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone… | Phase1 | Breast Cancer | Terminated | 2023-01-09 | 2024-04-25 | ClinicalTrials.gov |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | Phase1 | Breast Cancer | Completed | 2017-11-15 | 2024-06-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05671835 |
| TTI-101 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05671835 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| ribociclib | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| fulvestrant | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| Aromatase inhibitor (AI) | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| Palbociclib | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| TTI-101 | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| ribociclib | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| fulvestrant | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| Aromatase inhibitor (AI) | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| Palbociclib | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| TTI-101 | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| TTI-101 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT03195699 |
| TTI-101 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT03195699 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05671835 |
| TTI-101 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05671835 |
| TTI-101 | Other | Phase EARLY_PHASE1 | Squamous Cell Carcinoma of Head and Neck | WITHDRAWN | NCT05845307 |
| Control Group | Other | Phase EARLY_PHASE1 | Squamous Cell Carcinoma of Head and Neck | WITHDRAWN | NCT05845307 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT05668949 |
| TTI-101 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT05668949 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Stereotactic body radiation therapy | Drug | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| TTI-101 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Pembrolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | Other | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| ribociclib | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| fulvestrant | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| Aromatase inhibitor (AI) | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| Palbociclib | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |
| Placebo | DRUG | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05671835 |
| Stereotactic body radiation therapy | RADIATION | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT06141031 |
| Bevacizumab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Atezolizumab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| Control Group | DRUG | Phase EARLY_PHASE1 | Squamous Cell Carcinoma of Head and Neck | WITHDRAWN | NCT05845307 |
| Pembrolizumab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | RECRUITING | NCT05440708 |
| TTI-101 | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05384119 |